Anti-cancer agent 3-bromopyruvate reduces growth of MPNST and inhibits metabolic pathways in a representative in-vitro model.
Christian LinkeMarkus WösleAnja HarderPublished in: BMC cancer (2020)
Aggressive MPNST cells are sensitive to 3-BrPA therapy in-vitro with and without starvation. In a PA28 overexpression cancer cell model leading to p53 inactivation, thereby reflecting a key molecular feature in human NF1 associated MPNST, known functions of 3-BrPA to block mitochondrial activity and glycolysis were reproduced, however oncogenic cells displayed a partial resistance. To conclude, 3-BrPA was sufficient to reduce NF1 associated MPNST viability potentially due inhibition of glycolysis which should lead to the initiation of further studies and promises a potential benefit for NF1 patients.
Keyphrases
- induced apoptosis
- signaling pathway
- oxidative stress
- cell cycle arrest
- pi k akt
- lps induced
- end stage renal disease
- nuclear factor
- ejection fraction
- endothelial cells
- endoplasmic reticulum stress
- cell proliferation
- newly diagnosed
- transcription factor
- chronic kidney disease
- machine learning
- stem cells
- prognostic factors
- cross sectional
- deep learning
- mesenchymal stem cells
- human health
- cell therapy
- case control